8-K: Coya Therapeutics Reports Fiscal Year 2023 Results and Provides Corporate Update

Coya Therapeutics announced its 2023 financial results and provided a corporate update, highlighting progress in its clinical programs and strategic collaborations.

Summary

• Coya Therapeutics reported a net loss of $8.0 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in 2022.
• The company's research and development expenses increased to $5.5 million in 2023 from $4.4 million in 2022, primarily due to increased preclinical expenses.
• General and administrative expenses rose to $7.8 million in 2023 from $4.8 million in 2022, driven by increased personnel and professional fees.
• Coya closed an IPO in January 2023, generating net proceeds of $14.1 million, and a private placement in December 2023, generating net proceeds of $24.0 million.
• The company entered into a collaboration with Dr. Reddy's for COYA 302, potentially receiving up to $733 million in upfront and milestone payments plus royalties.
• Coya's cash and cash equivalents totaled $32.6 million as of December 31, 2023, with an additional $7.5 million received in January 2024 from Dr. Reddy's.
• The company anticipates filing an IND for COYA 302 in the second quarter of 2024 and initiating a Phase 2 trial in ALS, with topline data expected in 2025.
• Coya is expanding the development of COYA 302 to include Frontotemporal Dementia, Parkinson's disease, and Alzheimer's disease.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant clinical and financial progress, strong collaborations, and a clear path forward. The company has secured funding and is advancing its pipeline, which is viewed favorably by investors.

Positives

• Coya secured significant funding through an IPO and private placement, providing a cash runway into 2026.
• The collaboration with Dr. Reddy's for COYA 302 provides substantial financial upside through milestone payments and royalties.
• Positive clinical data from proof-of-concept studies in ALS and Alzheimer's disease supports the potential of Coya's therapeutic approach.
• The expansion of COYA 302's development to include multiple neurodegenerative diseases increases its potential market.
• The company has strengthened its management team with key appointments.
• Coya has expanded its patent estate, protecting its intellectual property.

Negatives

• The company reported a net loss of $8.0 million for 2023.
• Research and development expenses increased, primarily due to preclinical expenses.
• General and administrative expenses also increased due to personnel and professional fees.

Risks

• The company's success depends on the outcome of clinical trials and regulatory approvals.
• There are risks associated with the development and commercialization of new therapeutics.
• The company operates in a competitive and rapidly changing environment.
• Coya is dependent on third-party manufacturers.
• The company may need to raise additional capital in the future.

Future Outlook

Coya anticipates filing an IND for COYA 302 in the second quarter of 2024 and initiating a Phase 2 trial in ALS, with topline data expected in 2025. The company also plans to file an IND for COYA 302 in FTD in the second half of 2024 and initiate a trial shortly thereafter, with topline data expected in 2025. Coya will leverage data from the Phase 2 LD IL-2 study in AD to inform on strategy and next steps for COYA 302 in AD.

Management Comments

• We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya, commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
• The year began with the closing of our IPO and ended with a pivotal commercialization deal with Dr. Reddys for our lead drug candidate COYA 302 in ALS and an equity offering that together provide a meaningful cash runway into 2026, along with significant financial upside from additional future milestone payments and royalties upon commercialization in ALS.
• Our clinical evidence to date, much of which was presented in 2023 in various forums and is the basis of our path forward with COYA 302, points to combination biologics with our LD IL-2 as a potential next-generation therapeutic approach to treat complex immune pathways in neurodegenerative diseases.
• We see very similar disease pathways in ALS, FTD, PD, and AD and believe the restoration of regulatory T cells, or Tregs, while simultaneously inhibiting other inflammatory cell types, may be a meaningful approach to ultimately help millions of patients who suffer from these debilitating diseases that have very few, if any, proven treatment options.
• Similar to the historical treatment progression seen in oncology and viral disease indications, combination therapy may offer unique opportunities to treat complex, multi-pathway diseases in the neurodegenerative world.
• The results from our proof-of-concept trial in ALS patients demonstrated that LD IL-2 + CTLA4-Ig was able to essentially stop the signs of disease progression at 24 weeks (as measured by the ALSFRS-R Rating Scale) and meaningfully slow progression at 48 weeks in a population that normally deteriorates at a fairly steady rate with each passing month.
• We anticipate filing the IND for COYA 302 in 2Q24 and subsequently initiating our Ph. 2 trial in ALS to substantiate these initial findings.
• Topline data from this trial is expected in 2025.
• We also expanded COYA 302 into PD, FTD, and AD, given our research and clinical findings in a proof-of-concept trial that showed LD IL-2 was able to improve cognitive function in AD patients after four months of treatment.
• While this monotherapy data is clearly intriguing, we believe that treating PD, FTD, and AD patients with our combination therapy of COYA 302, our LD IL-2 and the immunomodulatory CTLA4-Ig, may offer an even better approach in these patient populations, given what we believe are similar underlying multiple, complex pathways.
• In fall of 2023, we completed enrollment of a Ph. 2 investigator initiated trial evaluating LD IL-2 in AD.
• The results from that trial, expected during summer of 2024, are expected to serve as the basis for the design of a future trial with COYA 302 in AD patients.
• Additionally, we anticipate filing an IND in the second half of 2024 to evaluate COYA 302 in patients with FTD and initiating that trial shortly thereafter.
• Topline data from this Ph. 2 trial in FTD is expected in 2025.
• Thus, one can see why we now refer to COYA 302 as a Pipeline in a Product.
• ALS is our lead indication, but many other larger neurodegenerative patient populations also stand to benefit given the common disease pathways involved.
• As we release additional clinical data and biomarker data across these numerous neurodegenerative diseases in 2024 and execute on the clinical milestones I have mentioned, we hope it becomes clear why we believe in our science and our clinical and regulatory pathways.

Industry Context

Coya's focus on regulatory T cells (Tregs) and their role in neurodegenerative diseases aligns with a growing interest in immunomodulatory therapies for these conditions. The company's approach of combining LD IL-2 with CTLA4-Ig is a novel strategy that could potentially address the complex immune pathways involved in diseases like ALS, Alzheimer's, FTD, and Parkinson's. The collaboration with Dr. Reddy's also highlights the increasing trend of partnerships between biotech companies and larger pharmaceutical firms to accelerate drug development and commercialization.

Comparison to Industry Standards

• Coya's approach of using low-dose IL-2 to enhance Treg function is similar to strategies being explored by other companies in the immuno-oncology and autoimmune space, such as XOMA and Bristol Myers Squibb, but Coya is focusing on neurodegenerative diseases.
• The use of CTLA4-Ig, an immunomodulatory drug, is also a common approach in autoimmune diseases, with companies like Abgenix and Medarex having developed similar therapies.
• The $733 million potential milestone payments from Dr. Reddy's are significant and comparable to other licensing deals in the biotech industry, such as the $1.2 billion deal between BioNTech and Genmab for cancer therapies.
• Coya's focus on combination therapies is also in line with the industry trend of exploring multi-targeted approaches to treat complex diseases, similar to the strategies used in oncology and viral diseases.
• The company's reported R&D expenses of $5.5 million are relatively low compared to larger biotech companies, but this is expected for a company at Coya's stage of development.

Management Changes

Stakeholder Impact

• Shareholders benefit from the company's progress in clinical development and strategic collaborations, which have the potential to increase the company's value.
• Employees benefit from the company's growth and expansion, which may lead to new opportunities.
• Patients with neurodegenerative diseases may benefit from the development of new therapies.
• The collaboration with Dr. Reddy's may benefit both companies through shared resources and expertise.
• Suppliers and creditors may benefit from the company's financial stability and growth.

Next Steps

• Coya plans to file an IND for COYA 302 in the second quarter of 2024.
• The company will initiate a Phase 2 trial of COYA 302 in ALS following the IND filing.
• Topline data from the Phase 2 trial in ALS is expected in 2025.
• Coya plans to file an IND for COYA 302 in FTD in the second half of 2024.
• The company will initiate a Phase 2 trial of COYA 302 in FTD shortly after the IND filing.
• Topline data from the Phase 2 trial in FTD is expected in 2025.
• Coya will use data from the Phase 2 LD IL-2 study in AD to inform the strategy for COYA 302 in AD.

Key Dates

Keywords

COYA 302, Regulatory T cells, Tregs, Neurodegenerative diseases, Amyotrophic Lateral Sclerosis, ALS, Alzheimer's disease, Frontotemporal Dementia, Parkinson's disease, Clinical trials, Biologics, Immunomodulatory, LD IL-2, CTLA4-Ig, Biomarkers